Gene therapy for human α1-antitrypsin deficiency in an animal model using SV40-Derived vectors

Yu–You Duan,Jian Wu,Jian–Liang Zhu,Shu–Ling Liu,Iwata Ozaki,David S. Strayer,Mark A. Zern

DOI: https://doi.org/10.1053/j.gastro.2004.07.058

IF: 29.4

2004-01-01

Gastroenterology

Abstract:Background & Aims: In most genetic diseases, the goal of gene therapy is to deliver a particular transgene; however, sometimes a deleterious gene product must be eliminated. Because of the promise of recombinant simian virus 40 (rSV40) vectors, we tested their ability to deliver a transgene and to target a transcript for destruction by direct administration of the vectors to the liver of an animal model for human α 1 -antitrypsin (α 1 -AT) deficiency. Methods: Therapy of human α 1 -AT deficiency requires stable transduction of resting hepatocytes, both to deliver wild-type α 1 -AT and to inhibit production of mutant α 1 -AT. Transgenic mice carrying the mutant human α 1 -AT PiZ allele were treated through an indwelling portal vein catheter with a simian virus 40 (SV40)-derived vector carrying a ribozyme designed to target the human transcript. Results: Treated transgenic mice showed marked decreases of human α 1 -AT messenger RNA and the protein in the liver, and serum levels of human α 1 -AT were decreased to 50% ± 5% of pretreatment values 3–16 weeks after transduction. Moreover, when normal mice were treated with an SV40-derived vector containing a modified human α 1 -AT complementary DNA engineered to be resistant to cleavage by the α 1 -AT ribozyme, they expressed human α 1 -AT messenger RNA and protein in their livers and serum levels of human α 1 -AT remained >1 μg/mL for 1 year. Conclusions: These results represent the initial steps toward a novel approach to the gene therapy of α 1 -AT deficiency.